These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 37257891)

  • 1. Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study.
    Ballouz T; Menges D; Anagnostopoulos A; Domenghino A; Aschmann HE; Frei A; Fehr JS; Puhan MA
    BMJ; 2023 May; 381():e074425. PubMed ID: 37257891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study.
    Menges D; Ballouz T; Anagnostopoulos A; Aschmann HE; Domenghino A; Fehr JS; Puhan MA
    PLoS One; 2021; 16(7):e0254523. PubMed ID: 34252157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-COVID-19 Condition Fatigue Outcomes Among Danish Residents.
    O'Regan E; Spiliopoulos L; Bech Svalgaard I; Nielsen NM; Vedel Sørensen AI; Bager P; Videbech P; Ethelberg S; Koch A; Hviid A
    JAMA Netw Open; 2024 Oct; 7(10):e2434863. PubMed ID: 39374018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Symptom trajectories of post-COVID sequelae in patients with acute Delta or Omicron infection in Bergen, Norway.
    Iversen A; Blomberg B; Haug K; Kittang B; Özgümüs T; Cox RJ; Langeland N
    Front Public Health; 2024; 12():1320059. PubMed ID: 38504678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021.
    ; Wulf Hanson S; Abbafati C; Aerts JG; Al-Aly Z; Ashbaugh C; Ballouz T; Blyuss O; Bobkova P; Bonsel G; Borzakova S; Buonsenso D; Butnaru D; Carter A; Chu H; De Rose C; Diab MM; Ekbom E; El Tantawi M; Fomin V; Frithiof R; Gamirova A; Glybochko PV; Haagsma JA; Haghjooy Javanmard S; Hamilton EB; Harris G; Heijenbrok-Kal MH; Helbok R; Hellemons ME; Hillus D; Huijts SM; Hultström M; Jassat W; Kurth F; Larsson IM; Lipcsey M; Liu C; Loflin CD; Malinovschi A; Mao W; Mazankova L; McCulloch D; Menges D; Mohammadifard N; Munblit D; Nekliudov NA; Ogbuoji O; Osmanov IM; Peñalvo JL; Petersen MS; Puhan MA; Rahman M; Rass V; Reinig N; Ribbers GM; Ricchiuto A; Rubertsson S; Samitova E; Sarrafzadegan N; Shikhaleva A; Simpson KE; Sinatti D; Soriano JB; Spiridonova E; Steinbeis F; Svistunov AA; Valentini P; van de Water BJ; van den Berg-Emons R; Wallin E; Witzenrath M; Wu Y; Xu H; Zoller T; Adolph C; Albright J; Amlag JO; Aravkin AY; Bang-Jensen BL; Bisignano C; Castellano R; Castro E; Chakrabarti S; Collins JK; Dai X; Daoud F; Dapper C; Deen A; Duncan BB; Erickson M; Ewald SB; Ferrari AJ; Flaxman AD; Fullman N; Gamkrelidze A; Giles JR; Guo G; Hay SI; He J; Helak M; Hulland EN; Kereselidze M; Krohn KJ; Lazzar-Atwood A; Lindstrom A; Lozano R; Malta DC; Månsson J; Mantilla Herrera AM; Mokdad AH; Monasta L; Nomura S; Pasovic M; Pigott DM; Reiner RC; Reinke G; Ribeiro ALP; Santomauro DF; Sholokhov A; Spurlock EE; Walcott R; Walker A; Wiysonge CS; Zheng P; Bettger JP; Murray CJL; Vos T
    JAMA; 2022 Oct; 328(16):1604-1615. PubMed ID: 36215063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study.
    Huang L; Li X; Gu X; Zhang H; Ren L; Guo L; Liu M; Wang Y; Cui D; Wang Y; Zhang X; Shang L; Zhong J; Wang X; Wang J; Cao B
    Lancet Respir Med; 2022 Sep; 10(9):863-876. PubMed ID: 35568052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-acute sequelae of covid-19 six to 12 months after infection: population based study.
    Peter RS; Nieters A; Kräusslich HG; Brockmann SO; Göpel S; Kindle G; Merle U; Steinacker JM; Rothenbacher D; Kern WV;
    BMJ; 2022 Oct; 379():e071050. PubMed ID: 36229057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptom Burden and Immune Dynamics 6 to 18 Months Following Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2): A Case-control Study.
    Fjelltveit EB; Blomberg B; Kuwelker K; Zhou F; Onyango TB; Brokstad KA; Elyanow R; Kaplan IM; Tøndel C; Mohn KGI; Özgümüş T; Cox RJ; Langeland N;
    Clin Infect Dis; 2023 Feb; 76(3):e60-e70. PubMed ID: 35959897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and determinants of persistent symptoms after infection with SARS-CoV-2: protocol for an observational cohort study (LongCOVID-study).
    Mutubuki EN; van der Maaden T; Leung KY; Wong A; Tulen AD; de Bruijn S; Haverman L; Knoop H; Franz E; van Hoek AJ; van den Wijngaard CC
    BMJ Open; 2022 Jul; 12(7):e062439. PubMed ID: 35777877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term health consequences among individuals with SARS-CoV-2 infection compared to individuals without infection: results of the population-based cohort study CoMoLo Follow-up.
    Heidemann C; Sarganas G; Du Y; Gaertner B; Poethko-Müller C; Cohrdes C; Schmidt S; Schlaud M; Scheidt-Nave C
    BMC Public Health; 2023 Aug; 23(1):1587. PubMed ID: 37605232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and Severity of Symptoms 3 Months After Infection With SARS-CoV-2 Compared to Test-Negative and Population Controls in the Netherlands.
    van der Maaden T; Mutubuki EN; de Bruijn S; Leung KY; Knoop H; Slootweg J; Tulen AD; Wong A; van Hoek AJ; Franz E; van den Wijngaard CC
    J Infect Dis; 2023 Apr; 227(9):1059-1067. PubMed ID: 36477364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-COVID-19 Symptoms 2 Years After SARS-CoV-2 Infection Among Hospitalized vs Nonhospitalized Patients.
    Fernández-de-Las-Peñas C; Rodríguez-Jiménez J; Cancela-Cilleruelo I; Guerrero-Peral A; Martín-Guerrero JD; García-Azorín D; Cornejo-Mazzuchelli A; Hernández-Barrera V; Pellicer-Valero OJ
    JAMA Netw Open; 2022 Nov; 5(11):e2242106. PubMed ID: 36378309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of post-acute COVID-19 syndrome symptoms at different follow-up periods: a systematic review and meta-analysis.
    Alkodaymi MS; Omrani OA; Fawzy NA; Shaar BA; Almamlouk R; Riaz M; Obeidat M; Obeidat Y; Gerberi D; Taha RM; Kashour Z; Kashour T; Berbari EF; Alkattan K; Tleyjeh IM
    Clin Microbiol Infect; 2022 May; 28(5):657-666. PubMed ID: 35124265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review.
    Nasserie T; Hittle M; Goodman SN
    JAMA Netw Open; 2021 May; 4(5):e2111417. PubMed ID: 34037731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.
    Deckert A; Anders S; de Allegri M; Nguyen HT; Souares A; McMahon S; Boerner K; Meurer M; Herbst K; Sand M; Koeppel L; Siems T; Brugnara L; Brenner S; Burk R; Lou D; Kirrmaier D; Duan Y; Ovchinnikova S; Marx M; Kräusslich HG; Knop M; Bärnighausen T; Denkinger C
    Trials; 2021 Jan; 22(1):39. PubMed ID: 33419461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study.
    Mizrahi B; Sudry T; Flaks-Manov N; Yehezkelli Y; Kalkstein N; Akiva P; Ekka-Zohar A; Ben David SS; Lerner U; Bivas-Benita M; Greenfeld S
    BMJ; 2023 Jan; 380():e072529. PubMed ID: 36631153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long COVID-six months of prospective follow-up of changes in symptom profiles of non-hospitalised children and young people after SARS-CoV-2 testing: A national matched cohort study (The CLoCk) study.
    Stephenson T; Pinto Pereira SM; Nugawela MD; McOwat K; Simmons R; Chalder T; Ford T; Heyman I; Swann OV; Fox-Smith L; Rojas NK; Dalrymple E; Ladhani SN; Shafran R;
    PLoS One; 2023; 18(3):e0277704. PubMed ID: 36877677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long COVID outcomes following omicron wave in non-hospital population.
    Ruiyin W; Qi J; Tingting W; Yuqin Y; Yan J; Kun P
    Front Public Health; 2024; 12():1377866. PubMed ID: 38560433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 infection is associated with self-reported post-acute neuropsychological symptoms within six months of follow-up.
    Andronescu LR; Richard SA; Scher AI; Lindholm DA; Mende K; Ganesan A; Huprikar N; Lalani T; Smith A; Mody RM; Jones MU; Bazan SE; Colombo RE; Colombo CJ; Ewers E; Larson DT; Maves RC; Berjohn CM; Maldonado CJ; English C; Sanchez Edwards M; Rozman JS; Rusiecki J; Byrne C; Simons MP; Tribble D; Burgess TH; Pollett SD; Agan BK
    PLoS One; 2024; 19(4):e0297481. PubMed ID: 38626117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.